Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (171-180 of 470) with videos related to

Pageof 47
Sort By:
International Journal of Biological Sciences|November 23, 2019
Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)Jillian Wilhelmina Paulina Bracht, Niki Karachaliou, Jordi Berenguer, et al.
Annals of Translational Medicine|November 26, 2015
Other targeted drugs in melanomaMaría González-Cao, Jordi Rodón, Niki Karachaliou, et al.
Future Oncology (London, England)|February 13, 2015
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trialFilippo de Marinis, Alain Vergnenegre, Antonio Passaro, et al.
Lung Cancer (Amsterdam, Netherlands)|November 26, 2002
Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancerJosé Miguel Sánchez, Carme Balañá, Albert Font, et al.
Lung Cancer (Amsterdam, Netherlands)|March 25, 2006
Applications of genomics in NSCLCRafael Rosell, Manuel Cobo, Dolores Isla, et al.
Investigational New Drugs|December 3, 2015
Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumorsSanjay Goel, Santiago Viteri, Teresa Morán, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2014
Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinomaJoaquim Bosch-Barrera, Elia Sais, Carol Lorencio, et al.
Pulmonary Pharmacology & Therapeutics|May 18, 2010
Biomarkers in lung oncologyRafael Rosell, Alain Vergnenegre, Baorui Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung CancerLaura Romero-Vielva, Santiago Viteri, Irene Moya-Horno, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2005
Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?Carlos Camps, Rafael Sirera, Roy Bremnes, et al.
Pageof 47

Showing results (171-180 of 470) with videos related to

Sort By:
Pageof 47
International Journal of Biological Sciences|November 23, 2019
Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)Jillian Wilhelmina Paulina Bracht, Niki Karachaliou, Jordi Berenguer, et al.
Annals of Translational Medicine|November 26, 2015
Other targeted drugs in melanomaMaría González-Cao, Jordi Rodón, Niki Karachaliou, et al.
Future Oncology (London, England)|February 13, 2015
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trialFilippo de Marinis, Alain Vergnenegre, Antonio Passaro, et al.
Lung Cancer (Amsterdam, Netherlands)|November 26, 2002
Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancerJosé Miguel Sánchez, Carme Balañá, Albert Font, et al.
Lung Cancer (Amsterdam, Netherlands)|March 25, 2006
Applications of genomics in NSCLCRafael Rosell, Manuel Cobo, Dolores Isla, et al.
Investigational New Drugs|December 3, 2015
Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumorsSanjay Goel, Santiago Viteri, Teresa Morán, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2014
Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinomaJoaquim Bosch-Barrera, Elia Sais, Carol Lorencio, et al.
Pulmonary Pharmacology & Therapeutics|May 18, 2010
Biomarkers in lung oncologyRafael Rosell, Alain Vergnenegre, Baorui Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung CancerLaura Romero-Vielva, Santiago Viteri, Irene Moya-Horno, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2005
Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?Carlos Camps, Rafael Sirera, Roy Bremnes, et al.
Pageof 47